NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2020.45 28.60 (1.44%)

35.30% Gain from 52W Low

246.0K NSE+BSE Volume

NSE 18 Mar, 2025 11:59 AM (IST)

92,241.8

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

US FDA Approval

Lupin gets US FDA tentative approval for Amifampridine tablets, with a market size of $306 million See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

09 Nov 2024

2020.45

1.44%

Lupin (BUY): In-line quarter; EBITDAM guidance increased to 25%

Buy: Lupin Ltd.

Recommendation Target

BOB Capital Markets Ltd.

LPC's earnings were in line with our estimates but beat street's estimates. EBITDA margin was 23% in Q2FY25

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

08 Aug 2024

2020.45

1.44%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We have BUY on the Stock

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

08 Aug 2024

2020.45

1.44%

Strong products line up to support growth

Buy: Lupin Ltd.

Recommendation Target

KRChoksey

LUPIN witnessed a strong 16.3% Y-o-Y (+12.9% Q-o-Q) rise in reported revenue to INR 56,003 Mn (vs. our estimate of INR 57,525 Mn) in Q1FY25.
Adj. net income grew at 242.8% Y-o-Y (+49.4% Q-o-Q) to INR 8,509 Mn (vs. our estimate of INR 6,151 Mn, a beat of 31.0%) in Q1FY25.

Lupin Ltd. is trading above its 30 day SMA of 2014.5

Lupin Ltd.

07 Aug 2024

2020.45

1.44%

Strong beat; US/India drive earnings

Neutral: Lupin Ltd.

Target

Motilal Oswal

LPC delivered a strong earnings beat in 1QFY25, led by a superior show in key markets (US/India), lower R&D spending and a low tax rate.

Lupin Ltd. is trading above its 30 day SMA of 2014.5

Lupin Ltd.

07 Aug 2024

2020.45

1.44%

Strong Q1; complex products to drive growth

Buy: Lupin Ltd.

Target

Sharekhan

Q1FY2025 numbers were strong, beating our estimates on all fronts. Sales grew by 16% y-o-y to Rs. 5514 crore (9% above our estimates), on a 28% y-o-y growth in North America region to Rs. 2041 crore.

Geojit BNP Paribas increased Hold price target of Lupin Ltd. to 2132.0 on 13 Mar, 2025.

Lupin Ltd.

10 Jul 2024

2020.45

1.44%

Launches critical for sustenance of turnaround

Sell: Lupin Ltd.

Target

ICICI Securities Limited

Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).

Lupin Ltd. has an average target of 2329.44 from 9 brokers.

Lupin Ltd.

15 May 2024

2020.45

1.44%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Geojit BNP Paribas increased Hold price target of Lupin Ltd. to 2132.0 on 13 Mar, 2025.

Lupin Ltd.

08 May 2024

2020.45

1.44%

Strong products line up to support growth

Accumulate: Lupin Ltd.

KRChoksey

Lupin reported a weaker quarterly revenue than expected. It reported 12.0% Y-o-Y (-4.6% Q-o-Q) rise in operating revenue to Rs. 49,608 Mn (estimated: Rs. 55,943 Mn) US market grew at 19.4% Y-o-Y (-1.4% Q-o-Q) to USD 209 Mn (estimated: USD 298 Mn), the third consecutive quarter of over USD 200 Mn revenue.